US FDA Joins Chorus Of Concerns About Results Of GAIN Act

It's too early to say whether program is working, FDA tell Congress; agency has awarded 147 QIDP designations, but none of 12 approved antibacterals have new mechanism of action.

Bacteria

The US FDA has now formally joined the growing chorus of concern about whether the Generating Antibiotics Incentives Now (GAIN) Act has been fulfilling its intended goal of incentivizing antibacterial drug development.

In a five-year progress report to Congress required by the GAIN Act, a series of provisions of the 2012...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from R&D

More from Pink Sheet